×
About 14,095 results

ALLMedicine™ Ankylosing Spondylitis Center

Research & Reviews  3,599 results

Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males With Active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Non-radiographic Axial Spondyloarthri...
https://clinicaltrials.gov/ct2/show/NCT03926195

Aug 5th, 2022 - The primary objective of this study is to evaluate the effect of filgotinib on semen parameters in adult males with active rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or non-radiographic axial spondyloarthritis. Results of t...

Natural History and Development of Spondyloarthritis
https://clinicaltrials.gov/ct2/show/NCT01422694

Aug 4th, 2022 - The purpose of this protocol is to study the natural history of spondyloarthritis (SpA) in children and adults. Spondyloarthritis encompasses a spectrum of immune-mediated inflammatory diseases that exhibit overlapping features, but differ from ot...

Progression of Spinal Fusion in Ankylosing Spondylitis
https://clinicaltrials.gov/ct2/show/NCT00085995

Aug 4th, 2022 - Spinal fusion is the clinical, radiological, and pathological hallmark of ankylosing spondylitis (AS). However, spinal fusion occurs slowly in AS. Serial radiographs rarely show changes over 2 years, and often 5 or more years are needed to demonst...

Different Covid-19 Outcomes Among Systemic Rheumatic Diseases: A Nation-wide Cohort Study.
https://doi.org/10.1093/rheumatology/keac422
Rheumatology (Oxford, England); Bournia VK, Fragoulis GE et. al.

Aug 4th, 2022 - To investigate Covid-19-associated risk of hospitalization and death in rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), systemic lupus erythematosus (SLE) and systemic sclerosis (SSc) in comparison with the gener...

Functional significance of the rare rs35667974 IFIH1 gene polymorphism, associated with...
https://doi.org/10.1080/08916934.2022.2103799
Autoimmunity Zervou MI, Andreou AC et. al.

Aug 4th, 2022 - Autoimmune diseases, which affect approximately 5% of human population, are a range of diseases in which the immune response to self-antigens results in damage or dysfunction of tissues. Recent genome wide association studies (GWAS) have successfu...

see more →

Guidelines  11 results

2019 Update of the American College of Rheumatology/Spondylitis Association of America/...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764882
Arthritis & Rheumatology (Hoboken, N.J.); Ward MM, Deodhar A et. al.

Aug 23rd, 2019 - To update evidence-based recommendations for the treatment of patients with ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (SpA). We conducted updated systematic literature reviews for 20 clinical questions on pharmacologi...

Responsible, Safe, and Effective Use of Antithrombotics and Anticoagulants in Patients ...
https://www.ncbi.nlm.nih.gov/pubmed/30717501
Pain Physician; Kaye AD, Manchikanti L et. al.

Feb 6th, 2019 - Interventional pain management involves diagnosis and treatment of chronic pain. This specialty utilizes minimally invasive procedures to target therapeutics to the central nervous system and the spinal column. A subset of patients encountered in ...

The effectiveness, safety, and economic evaluation of Korean medicine for unexplained i...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5779787
Medicine

Mar 6th, 2018 - Therapeutic targets have been defined for axial and peripheral spondyloarthritis (SpA) in 2012, but the evidence for these recommendations was only of indirect nature. These recommendations were re-evaluated in light of new insights. Based on the ...

2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis.
https://doi.org/10.1136/annrheumdis-2016-210770
Annals of the Rheumatic Diseases; van der Heijde D, Ramiro S et. al.

Jan 15th, 2017 - To update and integrate the recommendations for ankylosing spondylitis and the recommendations for the use of tumour necrosis factor inhibitors (TNFi) in axial spondyloarthritis (axSpA) into one set applicable to the full spectrum of patients with...

EULAR recommendations for cardiovascular disease risk management in patients with rheum...
https://doi.org/10.1136/annrheumdis-2016-209775
Annals of the Rheumatic Diseases; Agca R, Heslinga SC et. al.

Oct 5th, 2016 - Patients with rheumatoid arthritis (RA) and other inflammatory joint disorders (IJD) have increased cardiovascular disease (CVD) risk compared with the general population. In 2009, the European League Against Rheumatism (EULAR) taskforce recommend...

see more →

Drugs  870 results see all →

Clinicaltrials.gov  377 results

Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males With Active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Non-radiographic Axial Spondyloarthri...
https://clinicaltrials.gov/ct2/show/NCT03926195

Aug 5th, 2022 - The primary objective of this study is to evaluate the effect of filgotinib on semen parameters in adult males with active rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or non-radiographic axial spondyloarthritis. Results of t...

Natural History and Development of Spondyloarthritis
https://clinicaltrials.gov/ct2/show/NCT01422694

Aug 4th, 2022 - The purpose of this protocol is to study the natural history of spondyloarthritis (SpA) in children and adults. Spondyloarthritis encompasses a spectrum of immune-mediated inflammatory diseases that exhibit overlapping features, but differ from ot...

Progression of Spinal Fusion in Ankylosing Spondylitis
https://clinicaltrials.gov/ct2/show/NCT00085995

Aug 4th, 2022 - Spinal fusion is the clinical, radiological, and pathological hallmark of ankylosing spondylitis (AS). However, spinal fusion occurs slowly in AS. Serial radiographs rarely show changes over 2 years, and often 5 or more years are needed to demonst...

Evaluation of a Connected Interface to Improve the Quality of Life and the Disability of Patient With Rheumatic Diseases
https://clinicaltrials.gov/ct2/show/NCT05417477

Aug 4th, 2022 - Musculoskeletal pathologies constitute a major public health problem. Rheumatologists, whether they practice in private or hospital settings, play a major role in the management of responsible for these ailments. Due to the increase in life expect...

BETY-BIOPSYCHOSOCIAL QUESTIONNAIRE IN PARTİCİPANTS RECEIVING RADIOTHERAPY
https://clinicaltrials.gov/ct2/show/NCT05213416

Aug 3rd, 2022 - It is known that psycho-physiological processes affect the results of medical treatment in chronic diseases [1]. In oncological rehabilitation, the psychological, social and functional problems of individuals with cancer are considered together, a...

see more →

News  771 results

PsA: Long-term retention, efficacy, and safety of secukinumab in real world
https://www.mdedge.com/rheumatology/article/256697/psoriatic-arthritis/psa-long-term-retention-efficacy-and-safety

Jul 31st, 2022 - Key clinical point: Secukinumab demonstrated high retention rates, sustained efficacy, and a favorable safety profile for at least 2 years after initiation in a real-world population of patients with moderate-to-severe psoriatic arthritis (PsA). M.

Psoriatic Arthritis and the Disease Activity Measures Used in Practice and Clinical Trials
https://www.medscape.com/viewarticle/970781

Jul 20th, 2022 - This transcript has been edited for clarity. Stanley Cohen, MD: I am Dr Stanley Cohen and welcome to Medscape's InDiscussion series on psoriatic arthritis. This is episode 1 of the second season. Today we'll be discussing outcome measures, the dis...

Treat-to-Target With Tapering Proves Effective in PsA, AxSpA
https://www.medscape.com/viewarticle/976286

Jun 28th, 2022 - Aiming for a disease activity target while reducing biologic therapy could be a winning approach for patients with psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA), according to the results of a new study presented at the annual Europ...

Upadacitinib Recommended for Nonradiographic AxSpA in Europe
https://www.medscape.com/viewarticle/976301

Jun 28th, 2022 - Upadacitinib may soon be used for the treatment of nonradiographic axial spondyloarthritis (nr-axSpA) after the European Medicines Agency's Committee for Medicinal Products for Human Use gave it its stamp of approval last week. AbbVie, the drug's ...

Treat-to-target strategy with tapering proves effective in PsA and axSpA
https://www.mdedge.com/rheumatology/article/255773/psoriatic-arthritis/treat-target-strategy-tapering-proves-effective-psa
Thomas R. Collins

Jun 27th, 2022 - Aiming for a disease activity target while reducing biologic therapy could be a winning approach for patients with psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA), according to the results of a new study presented at the annual Europ.

see more →

Patient Education  10 results see all →